Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations I Ince, CAJ Knibbe, M Danhof, SN de Wildt Clinical pharmacokinetics 52, 333-345, 2013 | 105 | 2013 |
Gestation-specific changes in the anatomy and physiology of healthy pregnant women: an extended repository of model parameters for physiologically based pharmacokinetic … A Dallmann, I Ince, M Meyer, S Willmann, T Eissing, G Hempel Clinical pharmacokinetics 56, 1303-1330, 2017 | 102 | 2017 |
Physiologically based pharmacokinetic modeling of renally cleared drugs in pregnant women A Dallmann, I Ince, J Solodenko, M Meyer, S Willmann, T Eissing, ... Clinical pharmacokinetics 56, 1525-1541, 2017 | 77 | 2017 |
Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK–PD modeling I Ince, SN de Wildt, D Tibboel, M Danhof, CAJ Knibbe Drug discovery today 14 (5-6), 316-320, 2009 | 77 | 2009 |
A physiologically based pharmacokinetic model for pregnant women to predict the pharmacokinetics of drugs metabolized via several enzymatic pathways A Dallmann, I Ince, K Coboeken, T Eissing, G Hempel Clinical pharmacokinetics 57, 749-768, 2018 | 75 | 2018 |
Critical illness is a major determinant of midazolam clearance in children aged 1 month to 17 years I Ince, SN De Wildt, MYM Peeters, DJ Murry, D Tibboel, M Danhof, ... Therapeutic drug monitoring 34 (4), 381-389, 2012 | 55 | 2012 |
A novel maturation function for clearance of the cytochrome P450 3A substrate midazolam from preterm neonates to adults I Ince, SN de Wildt, C Wang, MYM Peeters, J Burggraaf, E Jacqz-Aigrain, ... Clinical pharmacokinetics 52, 555-565, 2013 | 54 | 2013 |
Applied concepts in PBPK modeling: how to extend an open systems pharmacology model to the special population of pregnant women A Dallmann, J Solodenko, I Ince, T Eissing CPT: pharmacometrics & systems pharmacology 7 (7), 419-431, 2018 | 45 | 2018 |
Evaluation of changes in oral drug absorption in preterm and term neonates for Biopharmaceutics Classification System (BCS) class I and II compounds AA Somani, K Thelen, S Zheng, MN Trame, K Coboeken, M Meyer, ... British Journal of Clinical Pharmacology 81 (1), 137-147, 2016 | 39 | 2016 |
Predictive pediatric modeling and simulation using ontogeny information I Ince, J Solodenko, S Frechen, A Dallmann, C Niederalt, J Schlender, ... The Journal of Clinical Pharmacology 59, S95-S103, 2019 | 30 | 2019 |
A generic framework for the physiologically‐based pharmacokinetic platform qualification of PK‐Sim and its application to predicting cytochrome P450 3A4–mediated drug–drug … S Frechen, J Solodenko, T Wendl, A Dallmann, I Ince, T Lehr, J Lippert, ... CPT: pharmacometrics & systems pharmacology 10 (6), 633-644, 2021 | 17 | 2021 |
Integration of physiological changes during the postpartum period into a PBPK framework and prediction of amoxicillin disposition before and shortly after delivery A Dallmann, A Himstedt, J Solodenko, I Ince, G Hempel, T Eissing Journal of pharmacokinetics and pharmacodynamics 47 (4), 341-359, 2020 | 16 | 2020 |
Predictive performance of physiology‐based pharmacokinetic dose estimates for pediatric trials: evaluation with 10 Bayer small‐molecule compounds in children I Ince, A Dallmann, S Frechen, K Coboeken, C Niederalt, T Wendl, ... The Journal of Clinical Pharmacology 61, S70-S82, 2021 | 15 | 2021 |
Clinical investigation of the biopharmaceutical characteristics of nifurtimox tablets–Implications for quality control and application H Stass, S Just, B Weimann, I Ince, S Willmann, E Feleder, C Freitas, ... European Journal of Pharmaceutical Sciences 166, 105940, 2021 | 8 | 2021 |
Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions S Willmann, K Coboeken, Y Zhang, H Mayer, I Ince, E Mesic, K Thelen, ... CPT: Pharmacometrics & Systems Pharmacology 10 (10), 1195-1207, 2021 | 7 | 2021 |
Physiologically-based pharmacokinetic (PBPK) exploration of extrinsic factors influencing vericiguat pharmacokinetics S Frechen, I Ince, A Dallmann, M Gerisch, N Jungmann, C Becker, ... European Heart Journal 41 (Supplement_2), ehaa946. 3329, 2020 | 4 | 2020 |
Physiologically based pharmacokinetic (PBPK) modelling of oral drug absorption in older adults–an AGePOP review C Demeester, D Robins, AE Edwina, J Tournoy, P Augustijns, I Ince, ... European Journal of Pharmaceutical Sciences, 106496, 2023 | 3 | 2023 |
Population pharmacokinetics of nifurtimox in adult and pediatric patients with Chagas disease I Ince, K Prins, S Willmann, G Sutter, E Hanze, F Sadre‐Marandi, H Stass, ... The Journal of Clinical Pharmacology 62 (10), 1273-1284, 2022 | 3 | 2022 |
Model‐informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease S Willmann, I Ince, M Ahsman, K Coboeken, Y Zhang, K Thelen, ... CPT: Pharmacometrics & Systems Pharmacology 11 (8), 1111-1121, 2022 | 3 | 2022 |
Nifurtimox for Treatment of Chagas Disease in Pediatric Patients: the Challenges of Applying Pharmacokinetic-Pharmacodynamic Principles to Dose Finding H Stass, I Ince, U Grossmann, B Weimann, S Willmann The AAPS Journal 24 (5), 92, 2022 | 2 | 2022 |